On October 19th, Li Yunlong, executive vice president of China Drug Administration and Research Association, Shi Liqiang, vice president and secretary general, and Zhang Yuanyuan, deputy director of the office, went to Wanbangde Pharmaceutical Group for on-site inspection. Tong Qingbo, director of Wenling Market Supervision Administration, and Jiang Zuowei, deputy director, accompanied the inspection. Zhao Shouming, chairman of the company, warmly received Li Yunlong, executive vice chairman, and held a symposium.

Executive Vice President Li Yunlong and his entourage visited the company's product exhibition hall and party building activity center successively. Then, accompanied by Deputy General Manager Chen An, he visited the outsourced production site of the Ginkgo Leaf Dropping Pills production workshop. During the visit, Executive Vice President Li Yunlong had a detailed understanding of the company's core product Ginkgo biloba drop pills from the selection of raw materials, production and processing technology, quality assurance to product delivery and a series of production process links. Wanbangde Pharmaceutical Group strictly follows GMP Standard organization of production, strict control of drug production quality and technological innovation have been fully affirmed.

At the symposium, Chairman Zhao Shouming focused on the planning and construction plan of Wanbangde Health Town. In the next few years, the company will invest heavily to build a 1 square kilometer area integrating pharmaceuticals, medical equipment, high-end medical care, and vocational schools. , leisure is equal to an ecological health service park. Deputy General Manager Chen An introduced the company's basic situation, key R&D projects in recent years and the company's development goals in the next five years. He pointed out that in recent years, the company's R&D team has shifted the focus of drug development to the secondary development of products, such as the new use of old drugs for the core product Ginkgo Biloba Dropping Pills. In addition, the company also focuses on the development of various dosage forms of the core variety Huperzine A in the future, such as Huperzine A injection, oral tablets, sustained-release preparations, etc. The future market prospects and application prospects of Huperzine A preparations will be inestimable. Chen An said that in the next five years, the group headquarters will firmly grasp the huge opportunities for the development of the big health industry, accelerate the pace of enterprise transformation and upgrading, strengthen investment in technological innovation, and strive for the strategic goal of entering China's top 100 pharmaceutical companies at the end of the "13th Five-Year Plan".

Executive Vice President Li Yunlong introduced the objectives, operation mechanism and management philosophy of the research society. During the talks, the two sides conducted in-depth exchanges focusing on important issues in China's drug safety supervision and management, discussing the realization path of China's drug safety social co-governance, and corporate integrity. Both sides expressed that they will combine strengths and complement each other in the field of drug safety supervision and management, build a sharing platform, and contribute to the healthy development of China's pharmaceutical industry and the social co-governance of China's drug safety.

The company's vice president Chen An introduced the company's products to the executive vice president Li Yunlong (fourth from the left) and the vice president and secretary-general Shi Liqiang (the first from the left).